INTRODUCTION {#s1}
============

In late December of 2019, a new infectious respiratory disease emerged in Wuhan, China. The pathogen was soon identified to be a novel coronavirus (CoV) ([@B1][@B2][@B3]), which was initially termed 2019-nCoV by the World Health Organization (WHO), and the disease was named 2019 coronavirus disease (COVID-19). Because 2019-nCoV shares a high degree of sequence identity to the severe acute respiratory syndrome CoV (SARS-CoV) that emerged previously and uses the same cell receptor, angiotensin-converting enzyme 2 (ACE2), for infection ([@B2], [@B4]), it was renamed SARS-CoV-2 by the *Coronaviridae* Study Group (CSG) of the International Committee on Taxonomy of Viruses (ICTV). As of 7 April 2020, a total of 1,214,466 confirmed COVID-19 cases, including 67,767 deaths, have been reported from 211 countries or regions ([www.who.int/emergencies/diseases/novel-coronavirus-2019](http://www.who.int/emergencies/diseases/novel-coronavirus-2019)). The pandemic has posed serious threats to global public health and economic and social stabilities, calling for the urgent development of vaccines and antiviral drugs.

CoVs, a large group of enveloped viruses with a single positive-stranded RNA genome, are genetically classified into four genera: *Alphacoronavirus*, *Betacoronavirus*, *Gammacoronavirus*, and *Deltacoronavirus* ([@B5], [@B6]). The six previously known CoVs that cause human disease include two alphacoronaviruses (human CoV NL63 \[HCoV-NL63\] and HCoV-229E) and four betacoronaviruses (HCoV-OC43, HCoV-HKU1, SARS-CoV, and Middle East respiratory syndrome CoV \[MERS-CoV\]). SARS-CoV-2 belongs to the *Betacoronavirus* genus and represents the seventh human CoV. Like other CoVs, SARS-CoV-2 uses a glycosylated, homotrimeric class I fusion spike (S) protein to gain entry into host cells ([@B7][@B8][@B9]). The S protein comprises the S1 and S2 subunits and exists in a metastable prefusion conformation. The S1 subunit, which contains a receptor-binding domain (RBD) capable of functional folding independently, is responsible for virus binding to the cell surface receptor. A recent study suggested that the ACE2-binding affinity of the RBD of SARS-CoV-2 is up to 20-fold higher than that of SARS-CoV, which may contribute to its significantly increased infectivity and transmissibility ([@B7]). Receptor binding is deemed to trigger large conformational changes in the S complex, which destabilize the prefusion trimer, resulting in shedding of the S1 subunit, and activate the fusogenic activity of the S2 subunit ([@B10][@B11][@B12]). As illustrated in [Fig. 1](#F1){ref-type="fig"}, the sequence structure of S2 contains an N-terminal fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), a transmembrane region (TM), and the cytoplasmic tail (CT). During the fusion process, the FP is exposed and inserts into the target cell membrane, leading S2 in a prehairpin intermediate that bridges the viral and cell membranes; then, three HR1 segments self-assemble a trimeric coiled-coil and three HR2 segments fold into the grooves on the surface of the HR1 inner core, thereby resulting in a six-helical bundle (6-HB) structure that drives the two membranes in close apposition for fusion.

![Schematic diagram of SARS-CoV-2 S protein and its peptide derivatives. (A) Functional domains of the S protein. SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; SD, subdomain; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connector domain; HR2, heptad repeat 2; TM, transmembrane domain; CT, cytoplasmic tail. The S1/S2 cleavage site (685/686) is marked. The HR1 and HR2 sequences and membrane-proximal external sequence (MPES) are listed. (B) HR2-derived fusion inhibitor peptides. chol, cholesterol.](JVI.00635-20-f0001){#F1}

Peptides derived from the HR1 and HR2 sequences of the class I viral fusion proteins have been demonstrated to possess antiviral activity through binding to the prehairpin intermediate, thus blocking the formation of the viral 6-HB core ([@B13]). These peptides have also been found to have activity against emerging CoVs, including SARS-CoV and MERS-CoV ([@B11], [@B14][@B15][@B16]). In response to the outbreak of SARS-CoV, a group of HR2-based peptides that could effectively inhibit viral infection was developed ([@B11], [@B16][@B17][@B19]). Recently, a pan-CoV fusion inhibitor, designated EK1, was created and showed inhibitory activities against diverse HCoVs, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, and HCoV-OC43 ([@B20]). However, the previously reported fusion inhibitor peptides often display low antiviral activities with 50% inhibitory concentrations (IC~50~) in micromolar ranges. In the past decade, we have dedicated our efforts to develop viral fusion inhibitors with improved pharmaceutical profiles, generating a group of lipopeptides with extremely potent antiviral activity ([@B21][@B22][@B26]). To fight the COVID-19 pandemic, here we applied our expertise to develop fusion inhibitors against SARS-CoV-2 infection. We found that, different from the S protein of SARS-CoV, the S protein of SARS-CoV-2 has a high cell fusion activity; then, we designed and characterized several lipopeptide-based fusion inhibitors with highly potent activities in inhibiting both SARS-CoV-2 and SARS-CoV.

RESULTS {#s2}
=======

SARS-CoV-2 uses ACE2 as a cell receptor, and its S protein displays high fusion activity. {#s2.1}
-----------------------------------------------------------------------------------------

Early in the study, we wanted to experimentally verify whether SARS-CoV-2 uses human ACE2 as a receptor for cell entry; thus, we generated pseudotyped lentiviral particles of its S protein. The SARS-CoV and vesicular stomatitis virus G glycoprotein (VSV-G) pseudoviruses were also prepared for comparison. As shown in [Fig. 2A](#F2){ref-type="fig"}, all three pseudoviruses efficiently infected 293T cells that stably overexpressed ACE2 (293T/ACE2 cells); however, the transduction of SARS-CoV-2 and SARS-CoV dramatically decreased in 239T cells which expressed a low level of endogenous ACE2. As a virus control, VSV-G pseudovirus entered 239T cells even more efficiently than it entered 293T/ACE2 cells.

![Functional characterization of the SARS-CoV-2 and SARS-CoV S proteins. (A) The infectivity of the SARS-CoV-2 and SARS-CoV pseudoviruses in 293T cells or 293T/ACE2 cells was determined by a single-cycle infection assay. (B) The fusogenic activity of the SARS-CoV-2 and SARS-CoV S proteins with 293T cells or 293T/ACE2 cells as a target was determined by a DSP-based cell fusion assay. (C and D) The fusion activities of S proteins in 293T cells (C) and 293T/ACE2 cells (D) were determined at different time points. The experiments were repeated three times, and the data are expressed as the means ± standard deviations.](JVI.00635-20-f0002){#F2}

We further compared the fusion activity of viral S protein in 293T and 293T/ACE2 cells by applying a dual-split-protein (DSP)-based cell-cell fusion assay. As shown in [Fig. 2B](#F2){ref-type="fig"}, the S proteins of both SARS-CoV-2 and SARS-CoV displayed weak fusion activity in 293T cells, but they showed significantly increased capacities to mediate cell fusion with 293T/ACE2 cells. These results demonstrate that the overexpression of ACE2 can promote the cell entry of both the SARS-CoV-2 and SARS-CoV pseudoviruses as well as S protein-mediated cell-cell fusion activity, verifying the functionality of ACE2 for SARS-CoV-2.

In both the 239T and 293T/ACE2 target cells, we observed that the S protein of SARS-CoV-2 had fusion activity significantly increased over that of the S protein of SARS-CoV. Therefore, we further compared the fusion activities of the viral S proteins at different time points. As shown in [Fig. 2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}, the SARS-CoV S protein exhibited no appreciable fusion activity until the effector cells and target cells were cocultured for 5 or 6 h; in sharp contrast, the SARS-CoV-2 S protein mediated a rapid and robust cell fusion reaction, as indicated by its fusion kinetic curves, especially in 293T/ACE2 cells.

Compared to SARS-CoV, SARS-CoV-2 might possess an enhanced HR1-HR2 interaction. {#s2.2}
-------------------------------------------------------------------------------

Similar to many class I fusion proteins, the interaction between the HR1 and HR2 domains of the CoV fusion protein S2 critically determines viral membrane fusion activity. SARS-CoV-2 has an HR1 sequence with nine amino acid substitutions compared to the HR1 sequence of SARS-CoV, and eight of these are located within the HR1 core site, whereas the two viruses share fully identical HR2 sequences ([Fig. 3A](#F3){ref-type="fig"}). In order to explore the mechanism underlying the highly active fusion activity of the SARS-CoV-2 S protein, we synthesized two peptides corresponding to the HR1 sequence, and their secondary structures were determined by circular dichroism (CD) spectroscopy. As shown in [Fig. 3B](#F3){ref-type="fig"}, the HR1 peptide derived from SARS-CoV-2, designated SARS2NP, showed a typical α-helical conformation with an α-helical content of 66%, whereas the HR1 peptide from SARS-CoV, designated SARS1NP, had an α-helical content of 41%. The thermal stability of the two peptides was further measured. As shown in [Fig. 3C](#F3){ref-type="fig"}, SARS2NP and SARS1NP exhibited melting temperature (*T~m~*) values of 48 and 40°C, respectively. Furthermore, we synthesized a peptide containing the HR2 sequence, termed IPB01, and its interactions with the two HR1 peptides were analyzed by CD spectroscopy. As shown in [Fig. 3D](#F3){ref-type="fig"} and [E](#F3){ref-type="fig"}, both SARS2NP and SARS1NP interacted with IPB01 to form complexes with typical α-helical structures, having *T~m~* values of 75 and 68°C, respectively. In comparison, the complex formed between the SARS2NP and IPB01 peptides was much more stable than the complex formed between the SARS1NP and IPB01 peptides. Taken together, these results suggest that SARS-CoV-2 may have evolved an increased interaction between the HR1 and HR2 domains in the S2 fusion protein compared to that in SARS-CoV, thus critically determining its high fusogenic activity.

![Interactions between the HR1 and HR2 peptides derived from the S2 proteins of SARS-CoV-2 and SARS-CoV. (A) Sequence comparison of the HR1 and HR2 domains in SARS-CoV-2 and SARS-CoV. The sequences in the dotted boxes represent the core sites that mediate the helical interaction between the HR1 and HR2 domains. (B to E) The α-helicity and thermostability of the HR1 peptides alone (B and C) or in complexes with an HR2 peptide (D and E) were determined by CD spectroscopy, in which the peptides or peptide mixtures were dissolved in PBS, with the final concentration of each peptide being 10 μM. The experiments were performed two times, and representative data are shown.](JVI.00635-20-f0003){#F3}

The cholesterylated peptide exhibits greatly increased α-helical stability and target-binding affinity compared to noncholesterylated peptide. {#s2.3}
----------------------------------------------------------------------------------------------------------------------------------------------

Emerging studies have demonstrated that lipid conjugation is a viable strategy to design peptide-based viral fusion inhibitors with enhanced antiviral activity and *in vivo* stability ([@B21][@B22][@B26]). The resulting lipopeptides are considered to interact preferentially with the viral and cell membranes, thus raising the local concentration of the inhibitors at the site where viral fusion occurs. According to our previous experiences, here we modified the HR2 peptide IBP01 by adding a cholesterol group to its C terminus, resulting in a lipopeptide termed IPB02, as illustrated in [Fig. 1B](#F1){ref-type="fig"}. We first applied CD spectroscopy to determine the structural properties of the inhibitors in the absence or the presence of a target mimic HR1 peptide. As shown in [Fig. 4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}, unconjugated IPB01 alone was largely in a random structure and its *T~m~* value could not be defined. In contrast, the lipopeptide IPB02 displayed markedly increased helix contents with a *T~m~* of 65°C. Next, we assessed the helical binding stability of the inhibitors with the two target mimic peptides, SARS2NP and SARS1NP. As shown in [Fig. 4C](#F4){ref-type="fig"} to [F](#F4){ref-type="fig"}, the lipopeptide-based complexes had sharply increased thermostabilities compared to the complexes formed by the template peptides. Specifically, the IPB02 and SARS2NP complex showed a *T~m~* of 89°C, which was 14°C higher than the *T~m~* of the IPB01 and SARS2NP complex (75°C); the IPB02 and SARS1NP complex also had a *T~m~* of 89°C, indicating a 21°C increase relative to that of the IPB0-based complex (68°C). Here the CD results demonstrated that the cholesterol-conjugated peptide IPB02 possesses significantly increased α-helical thermostability and target-binding affinity.

![Secondary structure and binding stability of fusion inhibitor peptides determined by CD spectroscopy. The α-helicity and thermostability of peptide inhibitors alone (A and B) or in complexes with the SARS-CoV-2 HR1 peptide (C and D) or the SARS-CoV HR1 peptide (E and F) were detected, with the final concentration of each peptide being 10 μM. The experiments were performed two times, and representative data are shown.](JVI.00635-20-f0004){#F4}

We also visualized the formed complexes by a native polyacrylamide gel electrophoresis (N-PAGE) method. As shown in [Fig. 5](#F5){ref-type="fig"}, the positively charged SARS2NP and SARS1NP may have migrated up and off the gel and, thus, no bands appeared, whereas IPB01 and IPB02 showed specific bands because they carried net negative charges. When an HR1 peptide and an inhibitor were mixed, new bands corresponding to the binding complexes emerged at the upper positions of the gel, which verified the interactions between them.

![Visualization of the interactions between HR1 peptides and inhibitors by N-PAGE analysis. Each of the peptides was used at a final concentration of 40 μM. The positively charged peptides SARS2NP and SARS1NP migrated up and off the gel; thus, no bands appeared. IPB01 or IPB02 alone and their complexes with SARS2NP or SARS1NP displayed specific bands because of their net negative charges. The experiments were repeated two times, and representative data are shown.](JVI.00635-20-f0005){#F5}

IPB02 is a highly potent fusion inhibitor of SARS-CoV-2 and SARS-CoV. {#s2.4}
---------------------------------------------------------------------

We next sought to determine the antiviral functions of the IPB01 and IPB02 peptides. First, their inhibitory activities on S protein-mediated cell-cell fusion were examined by the DSP-based cell fusion assay, as described above. As shown in [Fig. 6A](#F6){ref-type="fig"} and [Table 1](#T1){ref-type="table"}, both IPB01 and IPB02 potently inhibited the cell fusion mediated by the S protein of SARS-CoV-2, with mean IC~50~ values of 0.022 and 0.025 μM, respectively. Then, we conducted the single-cycle infection assay to measure the inhibitory activities of the peptides on pseudoviruses. Surprisingly, the unconjugated peptide IPB01 showed very weak or marginal activities in inhibiting the SARS-CoV-2 ([Fig. 6B](#F6){ref-type="fig"}) and SARS-CoV ([Fig. 6C](#F6){ref-type="fig"}) pseudoviruses; however, the lipopeptide IPB02 inhibited the two pseudoviruses with IC~50~s of 0.08 and 0.251 μM, respectively ([Table 1](#T1){ref-type="table"}). As expected, IPB01 and IPB02 had no inhibitory activity against a control pseudotype (VSV-G), indicating their antiviral specificities. Therefore, we conclude that IPB02 is a highly potent fusion inhibitor of SARS-CoV-2 and SARS-CoV.

![Inhibitory activity of IPB01 and IPB02 against SARS-CoV-2 and SARS-CoV. (A) Inhibition of the SARS-CoV-2 S protein-mediated cell-cell fusion by the inhibitors, determined by a DSP-based cell fusion assay. (B to D) The activity of IPB01 and IPB02 in inhibiting SARS-CoV-2 (B), SARS-CoV (C), and control pseudovirus VSV-G (D) was determined by a single-cycle infection assay. The experiments were repeated three times, and the data are expressed as the means ± standard deviations.](JVI.00635-20-f0006){#F6}

###### 

Structural and functional characterization of the activity of lipopeptide fusion inhibitors against SARS-CoV-2 and SARS-CoV[^*a*^](#T1F1){ref-type="table-fn"}

  Inhibitor   Inhibitory activity (IC~50~ \[μM\])   Helix content (%)   *T~m~* (°C)                           
  ----------- ------------------------------------- ------------------- --------------- ------ ---- ---- ---- ----
  IPB01       0.022 ± 0.005                         33.74 ± 11.827      \>50            \>50   59   39   75   68
  IPB02       0.025 ± 0.002                         0.08 ± 0.017        0.251 ± 0.118   \>50   60   45   89   89
  IPB03       0.015 ± 0.002                         0.947 ± 0.179       1.315 ± 0.463   \>50   50   34   47   46
  IPB04       0.033 ± 0.013                         0.218 ± 0.063       1.053 ± 0.444   \>50   60   49   77   77
  IPB05       \>5                                   \>25                \>25            \>50   ND   ND   ND   ND
  IPB06       \>5                                   \>25                \>25            \>50   ND   ND   ND   ND
  IPB07       0.017 ± 0.001                         0.993 ± 0.08        1.037 ± 0.836   \>50   55   33   47   45
  IPB08       4.66 ± 1.565                          1.738 ± 0.898       1.13 ± 0.472    \>50   ND   ND   ND   ND
  IPB09       \>5                                   \>25                \>25            \>50   ND   ND   ND   ND

![](JVI.00635-20-t0001)

The antiviral assays were repeated three times, and data are expressed as the means ± standard deviations. PV, pseudovirus. The CD experiment was repeated two times, and representative data are shown. ND, not done, owing to the solubility problem of the peptides in PBS.

Structural and functional characterization of lipopeptide inhibitors. {#s2.5}
---------------------------------------------------------------------

In light of the high binding and inhibitory activities of IPB02, we next focused on characterizing its structure-activity relationship (SAR). To this end, a panel of new lipopeptides was generated by sequence truncation or extension, and their antiviral capacities were examined. As shown in [Table 1](#T1){ref-type="table"}, IPB03 and IPB04, which had an N-terminal amino acid truncation, still maintained a very high potency in inhibiting the cell fusion activity of the SARS-CoV-2 S protein, but they exhibited an obviously reduced activity to block the cell entry activity of both the SARS-CoV-2 and SARS-CoV pseudoviruses. A further N-terminal truncation, as indicated by IPB05 and IPB06, resulted in inhibitors inactive at a high concentration. By adding 6 amino acids of the membrane-proximal external sequence (MPES) to the C terminus of IPB05, the resulting peptide, IPB07, regained antiviral activity, demonstrating the importance of MPES in the design of such CoV fusion inhibitors. A different construct, IPB08, was a C-terminally truncated inhibitor with IPB02 as the template, but its antiviral function was markedly impaired, underscoring the roles of C-terminal residues in IPB02. On the basis of the results presented above, it was expected that IPB09 with two terminal truncations was antivirally inactive. Indeed, the CD data suggested that both the N- and C-terminal sequences contributed critically to the binding of the inhibitors ([Table 1](#T1){ref-type="table"}). Comparison of IPB03 and IPB04 revealed that three amino acids (Ile-Asn-Ala) in the N terminus of IPB03 reversely impaired inhibitor binding.

DISCUSSION {#s3}
==========

In 2002, SARS-CoV suddenly emerged in Guangzhou, China, and its subsequent global spread was associated with 8,096 cases and 774 deaths. To fight against SARS-CoV, we took immediate actions with multiple research projects and achieved significant findings. First, we identified several viral antigens suitable for the development of diagnostic tools ([@B27][@B28][@B29]); second, we proposed for the first time that the S protein receptor-binding domain (RBD) can serve as an ideal subunit vaccine for emerging CoVs ([@B30][@B31][@B41]); third, we also reported the first peptide-based SARS-CoV fusion inhibitor with potential therapeutic and preventive efficacies ([@B11]).

To fight against the current pandemic of COVID-19, caused by SARS-CoV-2, we sprang into action to develop effective therapeutics and prophylactics. In this study, we focused on developing viral fusion inhibitor peptides with potent and broad antiviral activity. First, our experiments verified that, like SARS-CoV, SARS-CoV-2 also uses human ACE2 as a receptor for cell entry and infection; however, the S protein of SARS-CoV-2 has much higher activity to mediate cell-cell fusion. By analyzing the secondary structure and thermostability by CD spectroscopy, we found that the HR1 peptide derived from the S2 fusion protein of SARS-CoV-2 displays much higher α-helicity and thermostability than the HR1 peptide derived from the S2 fusion protein of SARS-CoV. Consistently, both the α-helical contents and melting temperature of the SARS-CoV-2 HR1 peptide complexed with an HR2-derived peptide are higher than those of the SARS-CoV HR1 peptide-based complex, suggesting a stronger interaction between the HR1 and HR2 sites for SARS-CoV-2 than for SARS-CoV. According to our experiences in the design of a lipopeptide fusion inhibitor against HIV, we modified the HR2 sequence-derived peptide IPB01 with a cholesterol group, resulting in the lipopeptide IPB02 with highly potent activities in inhibiting SARS-CoV-2 and SARS-CoV pseudoviruses as well as S protein-mediated cell-cell fusion activity. Moreover, the structure-activity relationships (SAR) of the HR2 sequence-based fusion inhibitors were characterized by applying a panel of truncated lipopeptides, which certified the roles of both the N-and C-terminal amino acid sequences in the design of a potent inhibitor against emerging CoVs. Combined, these data provide important information for understanding the fusion mechanism of emerging CoVs and for the development of antivirals that target the membrane fusion step.

The cell entry of CoVs depends on the binding of the viral S proteins to cellular receptors and on S protein priming by host cell proteases ([@B42][@B43][@B45]). Previous studies demonstrated that SARS-CoV enters the targeted cells mainly via an endosome membrane fusion pathway, where its S protein is cleaved by endosomal cysteine proteases cathepsin B and L (CatB/L) and activated ([@B46]). However, SARS-CoV also employs the plasma membrane-associated serine protease TMPRSS2 for S protein priming, and especially, TMPRSS2 but not CatB/L is essential for viral entry into primary target cells and for viral spread in the infected host ([@B44], [@B47][@B48][@B49]). It was also found that introducing a furin recognition site between the S1 and S2 subunits significantly increased the ability of the SARS-CoV S protein to mediate cellular membrane surface infection ([@B50]). Differently from SARS-CoV, SARS-CoV-2 induces typical syncytium formation in infected cells, suggesting that it mainly utilizes a plasma membrane fusion pathway for cell entry ([@B51]). Sequence analyses revealed that SARS-CoV-2 harbors the S1/S2 cleavage site in its S protein, although its roles in S protein-mediated membrane fusion and the viral life cycle need to be characterized ([@B4], [@B8]). One can speculate that furin-mediated precleavage at the S1/S2 site in infected cells may promote subsequent TMPRSS2-dependent cell entry, which is the case for MERS-CoV ([@B52], [@B53]). A recent study found that SARS-CoV-2 employs TMPRSS2 for S protein priming and that a TMPRSS2 inhibitor approved for clinical use can block entry ([@B4]). For most viruses, the plasma membrane fusion pathway is more efficient than the endosome membrane fusion pathway because the latter is prone to activating host antiviral immunity ([@B54], [@B55]). In this study, we have not only verified that ACE2 is a cell receptor but also demonstrated that the SARS-CoV-2 S protein evolves a significantly increased fusogenic activity relative to the S protein of SARS-CoV. Although our studies have also shown that the HR1 mutations in the S2 protein can greatly enhance the HR1-HR2 interaction and may thus be a crucial factor to determine the fusion activity of the SARS-CoV-2 S protein, other players in the fusion pathways may contribute in coordination with that. We also observed that the HR2-derived inhibitors were more effective in inhibiting the S protein-mediated cell fusion of SARS-CoV-2 than in inhibiting that of pseudoviruses, implying that SARS-CoV-2 may also adopt the endosome entry pathway. Very recently, Xia and coworkers also found similar phenomena with different experimental systems ([@B51], [@B56]). Indeed, it was found that cathepsin L is required for the cell entry of SARS-CoV-2 and that teicoplanin, a glycopeptide antibiotic, can specifically inhibit the entry ([@B57], [@B58]).

Repurposing of existing drugs represents a viable drug discovery strategy because their safety profiles, side effects, posologies, and drug interactions are known, and this knowledge may shorten the time to development as a therapeutic and reduce the cost of development compared to those required for *de novo* drug discovery. In the emergency of the COVID-19 pandemic, a group of nonspecific antiviral drugs, including interferon (IFN), lopinavir-ritonavir, chloroquine, remdesivir (GS-5734), and favipiravir (T-705), were quickly screened for anti-SARS-CoV-2 activity, and they have been used to treat infected patients ([@B59], [@B60]). Very recently, a clinical study suggested that the combination of hydroxychloroquine and azithromycin may provide synergistic effects when used to treat COVID-19 patients ([@B61]). Nonetheless, the development of specific drugs for the treatment of infections caused by emerging coronaviruses, including SARS-CoV-2 and SARS-CoV, is strongly required. As mentioned above, the entry of SARS-CoV-2 into lung cells may mainly depend on S protein activation by plasma TMPRSS2, and thus, a membrane fusion inhibitor might not need to be taken up into lung cells to unfold its antiviral activity, which may result in more potent inhibitory activity. We believe that the newly developed lipopeptide IPB02 represents an ideal candidate for optimization and development. In our future studies, we would like to confirm the antiviral activity of IPB02 and its derivatives with authentic SARS-CoV-2 infection and evaluate their *in vivo* therapeutic efficacy in animal models. The IPB02-based peptides can be more easily produced on a large scale and are more cost-effective than neutralizing antibodies and other large protein-based inhibitors. Furthermore, we think that a peptide inhibitor can be applied topically for the treatment and prevention of emerging CoVs.

MATERIALS AND METHODS {#s4}
=====================

Peptide synthesis. {#s4.1}
------------------

Peptides were synthesized on rink amide 4-methylbenzhydrylamine (MBHA) resin using a standard solid-phase 9-flurorenylmethoxycarbonyl (FMOC) protocol as described previously ([@B21]). Lipopeptides were produced by conjugating cholesterol succinate monoester to the C-terminal lysine residue. All peptides were N-terminally acetylated and C-terminally amidated, and they were purified by reverse-phase high-performance liquid chromatography (HPLC) to more than 95% homogeneity and characterized by mass spectrometry.

Single-cycle infection assay. {#s4.2}
-----------------------------

The infectivity of SARS-CoV-2, SARS-CoV, and vesicular stomatitis virus (VSV) for 293T cells or 293T cells stably expressing human ACE2 (293T/ACE2) was determined by a single-cycle infection assay as described previously ([@B62]). To produce pseudoviruses, 293T cells were cotransfected with a backbone plasmid (pNL4-3.luc.RE) that encodes an Env-defective, luciferase reporter-expressing HIV-1 genome and a plasmid expressing the S protein of SARS-CoV-2 or SARS-CoV or the G protein of VSV. Cell culture supernatants containing the released virions were harvested at 48 h posttransfection, filtrated, and stored at −80°C. To measure the inhibitory activity of peptide inhibitors, pseudoviruses were mixed with an equal volume of a serially 3-fold-diluted peptide and incubated at 37°C for 30 min. The mixture was then added to 293T/ACE2 cells at a density of 10^4^ cells/100 μl per plate well. After they were cultured at 37°C for 48 h, the cells were harvested and lysed in reporter lysis buffer, and luciferase activity was measured using luciferase assay reagents and a luminescence counter (Promega, Madison, WI, USA). The 50% inhibitory concentration (IC~50~) was calculated as the final cell culture concentration of an inhibitor that caused a 50% reduction in relative luminescence units (RLU) compared to the level of the virus control subtracted from that of the cell control.

Cell-cell fusion assay. {#s4.3}
-----------------------

A dual-split-protein (DSP)-based cell-cell fusion assay was used to detect SARS-CoV-2 or SARS-CoV S protein-mediated cell-cell fusion activity and the inhibitory activity of the peptides, as described previously ([@B62]). Briefly, a total of 1.5 × 10^4^ 293T cells (effector cells) were seeded in a 96-well plate and 1.5 × 10^5^/ml 293T or 293T/ACE2 cells (target cells) were seeded in a 10-cm culture dish, and then the cells were incubated at 37°C. On the next day, the effector cells were cotransfected with an S protein-expressing and a DSP~1--7~ plasmid, the target cells were transfected with a DSP~8--11~ plasmid, and then the cells were incubated at 37°C. After 24 h, a serially 3-fold-diluted peptide was added to the effector cells and the cells were incubated for 1 h; the target cells were resuspended at 3 × 10^5^/ml in prewarmed culture medium that contained EnduRen live cell substrate (Promega) at a final concentration of 17 ng/ml and incubated for 30 min. Then, 3 × 10^4^ target cells were transferred to the effector cells and the mixture of cells was spun down to maximize cell-cell contact. After incubation for 2 h, luciferase activity was measured and IC~50~ values were calculated as described above.

CD spectroscopy. {#s4.4}
----------------

The secondary structure and thermal stability of peptides or peptide complexes were determined by circular dichroism (CD) spectroscopy as described previously ([@B62]). Briefly, a peptide was dissolved in phosphate-buffered saline (PBS; pH 7.2) at a final concentration of 10 μM and incubated at 37°C for 30 min. CD spectra were acquired on a Jasco spectropolarimeter (model J-815) using a 1-nm bandwidth with a 1-nm step resolution from 195 to 270 nm at room temperature. The spectra were corrected by subtracting a solvent blank, and the α-helical content was calculated from the CD signal by dividing the mean residue ellipticity (\[θ\]) at 222 nm by a value of −33,000 degrees cm^2^ dmol^−1^, corresponding to a 100% helix. Thermal denaturation was conducted by monitoring the ellipticity change at 222 nm from 20 to 98°C at a rate of 2°C/min, and the melting temperature (*T~m~*) was defined as the midpoint of the thermal unfolding transition.

N-PAGE. {#s4.5}
-------

Native polyacrylamide gel electrophoresis (N-PAGE) was performed to determine the interaction between a SARS-CoV2 or a SARS-CoV S protein HR1-derived peptide and an HR2-derived peptide as described previously ([@B63]). Briefly, an HR1 peptide was mixed with an HR2 peptide at a final concentration of 40 μM, and the mixture was incubated at 37°C for 30 min. Tris-glycine native sample buffer was added to the mixture at a ratio of 1:1, and then the mixture was loaded onto a 10- by 1.0-mm Tris-glycine gel (20%) at 25 μl/well. Gel electrophoresis was done with a 100-V constant voltage at 4°C for 3 h. The gel was then stained with Coomassie blue and imaged with a Bio-Rad imaging system (Bio-Rad, Hercules, CA, USA).

Data availability. {#s4.6}
------------------

All data are fully available without restriction.
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